Metastatic pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors associated with poor prognosis and limited therapeutic options. Recent advances in oncology-related immunotherapy, specifically in targeting of programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathways, have identified a new treatment potential in a variety of tumors, including advanced and rare tumors. Only a fraction of patients being treated by immune checkpoint inhibitors have shown to benefit from it, displaying a need for strategies which identify patients who may most likely show a favorable response. Building on recent, promising outcomes in a clinical study of metastatic PPGL using pembrolizumab, a humanized IgG4κ monoclonal antibody targeting the PD-1/PD-L1 pathway, we examined PD-L1 and PD-L2 expression in relation to oncogenic drivers in our PPGL patient cohort to explore whether expression can predict metastatic potential and/or be considered a predictive marker for targeted therapy. We evaluated RNA expression in the NIH cohort of 48 patients with known genetic predisposition (sporadic; pseudohypoxia: SDHB, VHL, EPAS1, EGLN1; kinase signaling: RET, NF1) and 6 normal medulla samples (NAM). For comparison, 72 PPGL samples from The Cancer Genome Atlas (TCGA) were used for analysis of gene expression based on the variant status (pseudohypoxia: SDHB, VHL, EPAS1, EGLN1; kinase signaling: NF1, RET). Expression of PD-L1 was elevated in the PPGL cohort compared to normal adrenal medulla, aligning with the TCGA analysis, whereas PD-L2 was not elevated. However, expression of PD-L1 was lower in the pseudohypoxia cluster compared to the sporadic and the kinase signaling subtype cluster, suggesting that sporadic and kinase signaling cluster PPGLs could benefit from PD-1/PD-L1 therapy more than the pseudohypoxia cluster. Within the pseudohypoxia cluster, expression of PD-L1 was significantly lower in both SDHB- and non-SDHB-mutated tumors compared to sporadic tumors. PD-L1 and PD-L2 expression was not affected by the metastatic status. We conclude that PD-L1 and PD-L2 expression in our cohort of PPGL tumors was not linked to metastatic behavior, however, the presence of PPGL driver mutation could be a predictive marker for PD-L1-targeted therapy and an important feature for further clinical studies in patients with PPGL.

Faculty of Science and 1st Medical Faculty Charles University Prague Czechia

Institute of Biotechnology Czech Academy of Sciences Prague West Czechia

School of Pharmacy and Medical Science Griffith University Southport QLD Australia

Section on Medical Neuroendocrinology Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Bethesda MD United States

Zobrazit více v PubMed

Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363(8):711–23. doi: 10.1056/NEJMoa1003466 PubMed DOI PMC

Weber JS, O’Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. . Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol (2008) 26(36):5950–6. doi: 10.1200/JCO.2008.16.1927 PubMed DOI

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. . Nivolumab versus docetaxel in advanced nonsquamous non-Small-Cell lung cancer. N Engl J Med (2015) 373(17):1627–39. doi: 10.1056/NEJMoa1507643 PubMed DOI PMC

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet (2017) 389(10066):255–65. doi: 10.1016/S0140-6736(16)32517-X PubMed DOI PMC

Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, et al. . Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med (2018) 378(14):1277–90. doi: 10.1056/NEJMoa1712126 PubMed DOI PMC

Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, et al. . Phase 2 study of pembrolizumab in patients with advanced rare cancers. J ImmunoTherapy Cancer. (2020) 8(1):e000347. doi: 10.1136/jitc-2019-000347 PubMed DOI PMC

Nölting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, et al. . Personalized management of pheochromocytoma and paraganglioma. Endocrine Rev (2022) 43(2):199–239. doi: 10.1210/endrev/bnab019 PubMed DOI PMC

Ilanchezhian M, Jha A, Pacak K, Del Rivero J. Emerging treatments for Advanced/Metastatic pheochromocytoma and paraganglioma. Curr Treat Options Oncol (2020) 21(11):85. doi: 10.1007/s11864-020-00787-z PubMed DOI PMC

Wang K, Crona J, Beuschlein F, Grossman AB, Pacak K, Nölting S. Targeted therapies in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab (2022) 17:dgac471. doi: 10.1210/clinem/dgac471 PubMed DOI PMC

Rodriguez RR, Rizwan S, Alhamad K, Finley GG. The use of immunotherapy treatment in malignant pheochromocytomas/paragangliomas: a case report. J Med Case Rep (2021) 15(1):172. doi: 10.1186/s13256-021-02733-5 PubMed DOI PMC

Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, et al. . Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell (2017) 31(2):181–93. doi: 10.1016/j.ccell.2017.01.001 PubMed DOI PMC

Li X, Song W, Shao C, Shi Y, Han W. Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. Cell Mol Immunol (2019) 16(1):28–39. doi: 10.1038/s41423-018-0086-z PubMed DOI PMC

Ancevski Hunter K, Socinski MA, Villaruz LC. PD-L1 testing in guiding patient selection for PD-1/PD-L1 inhibitor therapy in lung cancer. Mol Diagnosis Ther (2018) 22(1):1–10. doi: 10.1007/s40291-017-0308-6 PubMed DOI PMC

Paver EC, Cooper WA, Colebatch AJ, Ferguson PM, Hill SK, Lum T, et al. . Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology. (2021) 53(2):141–56. doi: 10.1016/j.pathol.2020.10.007 PubMed DOI

Pinato DJ, Black JR, Trousil S, Dina RE, Trivedi P, Mauri FA, et al. . Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior. Oncoimmunology. (2017) 6(11):e1358332. doi: 10.1080/2162402X.2017.1358332 PubMed DOI PMC

Guo D, Zhao X, Wang A, Xie Q, Xu X, Sun J. PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas. Hum Pathol (2019) 86:155–62. doi: 10.1016/j.humpath.2018.10.041 PubMed DOI

Wachtel H, Fishbein L. Genetics of pheochromocytoma and paraganglioma. Curr Opin Endocrinol Diabetes Obes (2021) 28(3):283–90. doi: 10.1097/MED.0000000000000634 PubMed DOI

Fishbein L, Del Rivero J, Else T, Howe JR, Asa SL, Cohen DL, et al. . The north American neuroendocrine tumor society consensus guidelines for surveillance and management of metastatic and/or unresectable pheochromocytoma and paraganglioma. Pancreas. (2021) 50(4):469–93. doi: 10.1097/MPA.0000000000001792 PubMed DOI

Liu Z, Ma J, Jimenez C, Zhang M. Pheochromocytoma: A clinicopathologic and molecular study of 390 cases from a single center. Am J Surg Pathol (2021) 45(9):1155–65. doi: 10.1097/PAS.0000000000001768 PubMed DOI

Meng X, Huang Z, Teng F, Xing L, Yu J. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treat Rev (2015) 41(10):868–76. doi: 10.1016/j.ctrv.2015.11.001 PubMed DOI

Kim H, Chung JH. PD-L1 testing in non-small cell lung cancer: Past, present, and future. J Pathol Transl Med (2019) 53(4):199–206. doi: 10.4132/jptm.2019.04.24 PubMed DOI PMC

Fusco N, Vaira V, Righi I, Sajjadi E, Venetis K, Lopez G, et al. . Characterization of the immune microenvironment in malignant pleural mesothelioma reveals prognostic subgroups of patients. Lung Cancer. (2020) 150:53–61. doi: 10.1016/j.lungcan.2020.09.026 PubMed DOI

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. (2014) 515(7528):568–71. doi: 10.1038/nature13954 PubMed DOI PMC

Marletta S, Fusco N, Munari E, Luchini C, Cimadamore A, Brunelli M, et al. . Atlas of PD-L1 for pathologists: Indications, scores, diagnostic platforms and reporting systems. J Pers Med (2022) 12(7):1073. doi: 10.3390/jpm12071073 PubMed DOI PMC

Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, et al. . Up-regulation of PD-L1, IDO, and t(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5(200):200ra116. doi: 10.1126/scitranslmed.3006504 PubMed DOI PMC

Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res (2016) 22(8):1865–74. doi: 10.1158/1078-0432.CCR-15-1507 PubMed DOI

Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, et al. . Characterization of PD-L1 expression and associated T-cell infiltrates in metastatic melanoma samples from variable anatomic sites. Clin Cancer Res (2015) 21(13):3052–60. doi: 10.1158/1078-0432.CCR-14-3073 PubMed DOI PMC

Li H, Zhang Q, Shuman L, Kaag M, Raman JD, Merrill S, et al. . Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes. Sci Rep (2020) 10(1):1439. doi: 10.1038/s41598-020-58351-6 PubMed DOI PMC

Tufton N, Hearnden RJ, Berney DM, Drake WM, Parvanta L, Chapple JP, et al. . The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas. Endocrine-Related Cancer. (2022) 29(11):589–598. doi: 10.1530/ERC-22-0020 PubMed DOI PMC

Kraft S, Fernandez-Figueras MT, Richarz NA, Flaherty KT, Hoang MP. PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression. J Am Acad Dermatol (2017) 77(3):534–42. doi: 10.1016/j.jaad.2017.05.007 PubMed DOI

Ma W, Gilligan BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol (2016) 9(1):47. doi: 10.1186/s13045-016-0277-y PubMed DOI PMC

Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther (2016) 9:5023–39. doi: 10.2147/OTT.S105862 PubMed DOI PMC

Scheel AH, Dietel M, Heukamp LC, Jöhrens K, Kirchner T, Reu S, et al. . Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol (2016) 29(10):1165–72. doi: 10.1038/modpathol.2016.117 PubMed DOI

Hadrava Vanova K, Pang Y, Krobova L, Kraus M, Nahacka Z, Boukalova S, et al. . Germline SUCLG2 variants in patients with pheochromocytoma and paraganglioma. JNCI: J Natl Cancer Institute. (2021) 114(1):130–138. doi: 10.1093/jnci/djab158 PubMed DOI PMC

Crona J, Lamarca A, Ghosal S, Welin S, Skogseid B, Pacak K. Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis. Endocr Relat Cancer. (2019) 26(5):539–50. doi: 10.1530/ERC-19-0024 PubMed DOI PMC